Kyle Doherty

Zipalertinib demonstrated efficacy in pretreated NSCLC with EGFR exon 20 insertion mutations, meeting the primary endpoint of ORR in the REZILIENT1 study.

FDA Grants Breakthrough Status to Endometrial Cancer Assay

Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

Patients with mantle cell lymphoma and large clonal hematopoiesis clones had shorter progression-free and overall survival compared with those without clones.

The frontline combination of ibrutinib with venetoclax was associated with complete response and durable remission for older patients with MCL.

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.